Third Age Health Services (NZSE:TAH) Research & Development: NZ$0.00 Mil (TTM As of Mar. 2025)


NZSE:TAH Third Age Health Services Ltd NZSE:TAH
87 GF Score
Price NZ$4.40
GF Value NZ$3.39
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Third Age Health Services Research & Development?

Third Age Health Services NZSE:TAH 87 Research & Development is NZ$0.00 Mil as of Mar. 2025. GuruFocus rates NZSE:TAH with a GF Score™ of 87/100 and a GF Value™ of NZ$3.39 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Third Age Health Services's Research & Development for the six months ended in Mar. 2025 was NZ$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was NZ$0.00 Mil.

Third Age Health Services  (NZSE:TAH) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Third Age Health Services Research & Development Related Terms

Third Age Health Services Research & Development Historical Data

* Premium members only.

The historical data trend for Third Age Health Services's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Third Age Health Services Research & Development Chart

Third Age Health Services Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Third Age Health Services Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NZSE:TAH
87GF Score
Third Age Health Services Ltd NZSE:TAH
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Third Age Health Services Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NZ$0.00 Mil mean?
Third Age Health Services (NZSE:TAH) has a Research & Development of NZ$0.00 Mil as of Mar. 2025. Research and development expense is the total cost for research and development activities. View historical data on Third Age Health Services and its competitors.
Is Third Age Health Services' Research & Development too high?
Third Age Health Services' current Research & Development is NZ$0.00 Mil. Overall, Third Age Health Services has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Third Age Health Services' Research & Development compare to HCA and THC?
Third Age Health Services' Research & Development of NZ$0.00 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Third Age Health Services and its competitors. Third Age Health Services's current Research & Development is NZ$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Third Age Health Services stock overvalued right now?
Based on GuruFocus' analysis, Third Age Health Services (NZSE:TAH) is currently considered Modestly Overvalued. The stock's GF Value™ is NZ$3.39, compared to a current price of NZ$4.40 — trading 29.8% above its estimated fair value. The current Research & Development is NZ$0.00 Mil. Third Age Health Services' overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Third Age Health Services (NZSE:TAH), the current Research & Development is NZ$0.00 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Third Age Health Services (NZSE:TAH) Overvalued in 2026?

Based on GuruFocus' analysis, Third Age Health Services stock appears to be overvalued. The current stock price of NZ$4.40 is trading 29.8% above its estimated GF Value™ of NZ$3.39. GuruFocus considers Third Age Health Services to be Modestly Overvalued.

Key valuation signals for NZSE:TAH:

  • Research & Development: NZ$0.00 Mil
  • GF Value™: NZ$3.39 vs. price of NZ$4.40 (29.8% above fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the NZSE:TAH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Third Age Health Services Business Description

Address 536 Kennedy Road, Greenmeadows, Napier, NZL, 4112
Third Age Health Services Ltd is engaged in providing health care services to older adults residing in Aged Residential Care. The services offered by the company include 24/7 access to a doctor, Regular, scheduled rounds by a Practitioner, and Guaranteed locum cover. The company segment includes: Aged medical residential care services, being the provision of medical care services to the aged care sector. General practice medical services, being the provision of primary care services to the community.
87GF Score

Get the complete analysis for NZSE:TAH

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NZ$4.40
Price
NZ$3.39
GF Value